explore -WSS

explore

author：comprehensive 2025-08-06 04:47:10 - browse：77

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Resistance to opioid

focus

WSS

FDA's Pazdur wants cancer trials to range beyond China alone

Juul documents reveal insider tactics on political lobbying

NIH documents show early flaws of $1.6 billion long Covid program

ACIP vaccine advisory panel sees its vacancies filled

Too many hospitalized Covid

Eli Lilly reports tirzepatide MASH success during Q4 earnings

focus

explore

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Letters to First Opinion on caregivers, digital health, and more

ChatGPT in medicine: STAT answers readers' burning questions

Abbott's new heart device gets FDA advisory panel nod

Tori Bowie and the unacceptable rates of Black maternal death

The Pandemic Treaty must support building strong health systems

After affirmative action ruling, medical educators look to 'holistic review'

Woman returns to dialysis after doctors remove transplanted pig kidney

Moonlake's readout produced a cash windfall. Risks remain

Cord blood banking comes at a high cost to babies

hotspot

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

FDA's Pazdur wants cancer trials to range beyond China alone

The Pandemic Treaty must support building strong health systems

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

hotspot

focus

entertainment

focus